薬理と治療

Abstract

Objectives Chicken collagen hydrolysate（Chicken−Collagen Octa Peptides；C−COP）contains a peptide（Gly−Ala−Hyp−Gly−Leu−Hyp−Gly−Pro）with angiotensin converting enzyme （ACE）−inhibitory activity. Four weeks of C−COP administration at 2.9 g／day has already been found to reduce blood pressure in humans. Here, we investigate the safety of excess administration of lactic acid beverage containing C−COP. Methods A total of 48 subjects with mild hypertension or high−normal blood pressure were randomly assigned to two treatment groups：a test−food group in which subjects were given a lactic acid drink containing three times（8.7 g／day）the amount of C−COP usually given（2.9g／day）, and a placebo group in which subjects were given a dummy drink. The study period comprised a total of 6 weeks：4 weeks of treatment and a 2−week post−treatment observation period to investigate the parameters related to safety. Results No clinically meaningful adverse effects or abnormal changes in laboratory results due to intake of lactic acid beverage containing C−COP were observed. In addition, no subjects showed dramatic reductions in blood pressure or any hypotensive symptoms. Conclusions These results suggest that the lactic acid beverage containing C−COP has a high safety profile, even in the case of excess administration. （Jpn Pharmacol Ther 2008；36：549−59）KEY WORDS C−COP（Chicken−Collagen Octa Peptides）, ACE−inhibitory activity, Excess administration, Safety